Evidence map›Paper›PMID 39962429›Full record

ArticleBMC medical imaging2025

Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma.

Meng Wu, Haijia Yu, Siwen Pang, Aie Liu, Jianhua Liu

Abstract read
In one paragraph

Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meng WuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Haijia YuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Siwen PangDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Aie LiuDepartment of Research and Development, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, China.
Jianhua LiuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China. jian_hua@jlu.edu.cn.

Funding

The Excellent Youth Training Foundation of Jilin University, China No. 419080520665The Program of Youth Science and Technology Innovation and Entrepreneurship Outstanding Talents (Team) of Jilin Province, China No. 20230508063RC
6 · The paper itself

Abstract

backgroundTo investigate how effectively clinical features and CT-based radiomic features predict the pathological grade of hepatocellular carcinoma (HCC).

methodsWe retrospectively analyzed 108 patients diagnosed with hepatocellular carcinoma who underwent pathological examination between May 2020 and May 2024 at the Second Hospital of Jilin University. All patients underwent laboratory tests and contrast-enhanced computed tomography (CECT) scanning of the liver within one month prior to pathological examination. First, we analyzed laboratory tests, such as alpha fetoprotein (AFP) and des-γ-carboxy prothrombin (PIVKA-II), to identify risk factors associated with the pathological grading of HCC. Then, we built and evaluated the performance of the clinical model. Next, we imported the arterial-phase and venous-phase images of the CECT images into the uAI Research Portal research platform for 'one-stop' processing, which included semiautomatic ROI outlining, feature extraction, dimensionality reduction, model construction and evaluation. To evaluate the model's diagnostic effectiveness, receiver operating characteristic (ROC) curves were produced, and the related accuracy, sensitivity, specificity, and area under the curve (AUC) were computed. The models were compared using the Delong test, and the clinical value of the predictive model was assessed via the use of calibration curves and decision curve analysis (DCA) to quantify the agreement between the model and the actual outcomes.

resultsPoorly differentiated hepatocellular carcinoma (pHCC) is associated with risk variables such as hepatitis C virus antibodies(HCVAb), PIVKA-II, and sex. In the training and validation cohorts, the AUC values of the clinical model were 0.719 and 0.692, respectively; those of the AP model were 0.843 and 0.773; those of the VP model were 0.806 and 0.804; those of the AP + VP model were 0.953 and 0.844; and those of the AP + VP + clinical model were 0.926 (95% CI: 0.88-0.995) and 0.863 (95% CI: 0.711-1). The DCA curves revealed that the overall net benefit of the AP + VP + clinical model was greater than that of the other models and that it had the best diagnostic results.

conclusionsCT-based radiomic modeling combined with clinical features (sex) and laboratory tests (e.g., AFP and PIVKA-II) can reliably predict the pathological grade of HCC patients prior to surgery.

Indexed as

alpha-FetoproteinsBiomarkersCarcinoma, HepatocellularLiver NeoplasmsProtein PrecursorsTomography, X-Ray ComputedAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm GradingProthrombinRadiomicsacarboxyprothrombinAFP protein, humanalpha-FetoproteinsBiomarkersBiomarkers, TumorProtein PrecursorsProthrombinAFPHepatocellular carcinomaPathological gradePIVKA-IIRadiomics

Identifiers

PMID39962429
PMCPMC11834502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.